Inhibition of the Cardiac Angiogenic Response to Surgical FGF-2 Therapy in a Swine Endothelial Dysfunction Model

• DOI: 10.1161/01.cir.0000087903.75204.ad
• Publication Date: 2003-09-12T00:46:21Z
• Authors: Marc Ruel; Gui Fu Wu; Tanveer A. Khan; Pierre Voisine; Cesario Bianchi; Jianyi Li; Jian Li; Roger J. Laham; Frank W. Sellke
• Keywords: Therapeutic angiogenesis; Endothelial Dysfunction

Background— Discrepancy exists between the potent effects of therapeutic angiogenesis in laboratory animals and marginal results observed patients with advanced coronary artery disease. In vitro small animal data suggest that may depend on locally available nitric oxide (NO), but impact endothelial dysfunction myocardium has been unclear. We compared clinically applicable methods swine which was experimentally induced to normal swine. Methods Results— Miniswine were fed either a regular (N=13) or hypercholesterolemic diet for 20 weeks. Hypercholesterolemic showed videomicroscopy. Animals from both groups received 100 μg perivascular sustained-release fibroblast growth factor (FGF)-2 lateral myocardial territory, previously made ischemic by placement an ameroid constrictor around circumflex artery. After 4 weeks FGF-2 therapy, perfusion significantly lower than normocholesterolemic swine, at rest during pacing (0.44±0.04 versus 0.81±0.15 mL/min/g rest, respectively; P =0.006; 0.50±0.06 0.71±0.10 pacing; =0.02). no net increase treatment. Endothelial cell density FGF receptor-1 expression territory animals. Conclusions— The cardiac angiogenic response treatment using markedly inhibited dysfunction. These findings is major obstacle efficacy clinical protocols constitutes target toward making more effective